MSH2 and neoplasm: Our findings may, therefore, have direct implications for the utility of this ubiquitous and endogenous mutational signature as a mutational 'clock' since tumours with MBD4, MSH2 or MSH6 mutations will lead to an overestimation of mutational age when compared to BER/MMR-proficient tumours.